{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-168830","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.949716+00:00","generated_at":"2026-05-17T22:57:06.888761+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rein Therapeutics enters up to $21M financing with Yorkville via PPA and SEPA","bullets":["Pre-Paid Advance Agreement: up to $6M; initial $1M advance at 95% net ($0.95M); 8% annual interest rising to 18% on default.","Standby Equity Purchase Agreement: up to $15M over 36 months; shares sold at 96% of lowest 3-day VWAP.","Floor price set at $0.28 per share; Yorkville may require share issuance at lower of 115% of VWAP or 95% of lowest 7-day VWAP.","Commitment fee of $300k paid as 213,099 shares plus $25k structuring fees; Exchange Cap limited to 19.9% of outstanding shares.","Proceeds used for general corporate purposes; shares registered on Form S-3 (File No. 333-287342)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-168830","json":"https://secwatch.observer/filing/0001193125-25-168830.json","markdown":"https://secwatch.observer/filing/0001193125-25-168830.md","text":"https://secwatch.observer/filing/0001193125-25-168830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525168830/0001193125-25-168830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525168830/d56953d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:57:06.888761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a03ede5289f522ad48a1d6b94aef46fd04538bf","claim":"Rein Therapeutics, Inc. incurred credit facility of up to $6.0 million with YA II PN, Ltd. at 8%.","evidence_excerpt":"(the “Company”) entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, the Company may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525168830/0001193125-25-168830-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to $6.0 million"},{"label":"Counterparty","value":"YA II PN, Ltd."},{"label":"Rate","value":"8%"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}